{"protocolSection":{"identificationModule":{"nctId":"NCT02533453","orgStudyIdInfo":{"id":"D5551L00018"},"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.","officialTitle":"A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in Patients With Type 2 Diabetes Mellitus","acronym":"Bydureon"},"statusModule":{"statusVerifiedDate":"2019-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-01-28","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2016-12-07","type":"ACTUAL"},"completionDateStruct":{"date":"2016-12-07","type":"ACTUAL"},"studyFirstSubmitDate":"2015-08-11","studyFirstSubmitQcDate":"2015-08-25","studyFirstPostDateStruct":{"date":"2015-08-26","type":"ESTIMATED"},"resultsFirstSubmitDate":"2017-10-10","resultsFirstSubmitQcDate":"2019-02-14","resultsFirstPostDateStruct":{"date":"2019-05-31","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-02-14","lastUpdatePostDateStruct":{"date":"2019-05-31","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"As current study is conducted to provide additional information regarding safety and efficacy Bydureon, exenatide once weekly for injectable suspension, in the Korean population open label, non-comparative, multi-centre design is used."},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"],"keywords":["Type 2 Diabetes Mellitus, T2DM, GLP-1, GLP-1 Once weekly, Exenatide"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":110,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Bydureon","type":"EXPERIMENTAL","description":"exenatide once weekly","interventionNames":["Biological: Bydureon"]}],"interventions":[{"type":"BIOLOGICAL","name":"Bydureon","description":"exenatide once weekly","armGroupLabels":["Bydureon"],"otherNames":["exenatide"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With Adverse Events(AEs) and Serious Adverse Event(SAEs)","description":"was to estimate the incidence rates of adverse events (AEs) and serious adverse events (SAEs) in patients who are treated with 2 mg exenatide once weekly for type 2 diabetes mellitus in the normal clinical practice setting over a period of 12/24 weeks for long-term surveillance.","timeFrame":"baseline and 12/24 weeks"}],"secondaryOutcomes":[{"measure":"Change in HbA1c","description":"Change in HbA1c at 12 and 24 weeks from start of the treatment(24 weeks just for patients allocated in long-term treatment)","timeFrame":"baseline and 12/24 weeks"},{"measure":"Change in Fasting Plasma Gloucose","description":"Change in Fasting plasma gloucose at 12 and 24 weeks from start of the treatment(24 weeks just for patients allocated in long-term treatment)","timeFrame":"baseline and 12/24 weeks"},{"measure":"Change in Body Weight","description":"Change in body weight at 12 and 24 weeks from start of the treatment(24 weeks just for patients allocated in long-term treatment)","timeFrame":"baseline and 12/24 weeks"},{"measure":"Change in Vital Sign","description":"Change in vital sign at 12 and 24 weeks from start of the treatment(24 weeks just for patients allocated in long-term treatment)","timeFrame":"baseline and 12/24 weeks"},{"measure":"Evaluation of \"Subjective Improvement of Main Indication\"","description":"\"Subjective improvement of main indication\" will be assessed as \"improved,\" \"slightly improved,\" \"unchanged,\" \"aggravated,\" or \"unable to evaluate.\"","timeFrame":"baseline and 12/24 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female, 19-75 years of age\n* diagnosed with type 2 diabetes mellitus\n* Patients who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies;\n\n  * Metformin\n  * Sulphonylurea\n  * Thiazolidinedione\n  * Metformin and sulphonylurea\n  * Metformin and thiazolidinedione\n\nExclusion Criteria:\n\n* Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following medications:\n\n  1. Alpha glucosidase inhibitor or meglitinide within 30 days of screening;\n  2. Insulin within 2 weeks prior to screening or insulin for longer than 1 week within 3 months of screening;\n  3. DPP-4 inhibitors within 30 days of screening;\n  4. Regular use (\\> 14 days) of drugs that directly affect gastrointestinal motility within 3 months of screening;\n  5. Regular use (\\> 14 days) of systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption within 3 months of screening;\n  6. GLP-1 receptor agonist except exenatide within 3 months of screening;\n* diagnosed with type 1 diabetes mellitus or diabetic ketoacidosis;\n* type 2 diabetes by beta-cell dysfunction requiring insulin treatment\n* Has ever used exenatide\n* Pregnant or breast feeding patients\n* Hepatic disease (defined by aspartate or alanine transaminase \\>3.0 times the upper limit of normal\n* End-stage renal disease or severe renal impairment (creatinine clearance \\< 30 ml/min)","healthyVolunteers":false,"sex":"ALL","minimumAge":"19 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Research Site","city":"Busan","zip":"49241","country":"South Korea","geoPoint":{"lat":35.10168,"lon":129.03004}},{"facility":"Research Site","city":"Daegu","zip":"700-712","country":"South Korea","geoPoint":{"lat":35.87028,"lon":128.59111}},{"facility":"Research Site","city":"Daejeon","zip":"35015","country":"South Korea","geoPoint":{"lat":36.34913,"lon":127.38493}},{"facility":"Research Site","city":"Gwangju","zip":"61469","country":"South Korea","geoPoint":{"lat":35.15472,"lon":126.91556}},{"facility":"Research Site","city":"Incheon","zip":"405-760","country":"South Korea","geoPoint":{"lat":37.45646,"lon":126.70515}},{"facility":"Research Site","city":"Seongnam-si","zip":"13620","country":"South Korea","geoPoint":{"lat":37.43861,"lon":127.13778}},{"facility":"Research Site","city":"Seoul","zip":"03080","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Seoul","zip":"03722","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Seoul","zip":"05505","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Seoul","zip":"06351","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Seoul","zip":"06591","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Seoul","zip":"08308","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Seoul","zip":"130-872","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Suwon","zip":"16499","country":"South Korea","geoPoint":{"lat":37.29111,"lon":127.00889}},{"facility":"Research Site","city":"Wŏnju","zip":"26426","country":"South Korea","geoPoint":{"lat":37.35139,"lon":127.94528}}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"115 subjects were participated: 5 failed screening without treatment with the study drug.","recruitmentDetails":"Participants recruited from 15 hospitals in South Korea between Jan 2016 and Jul 2016.","groups":[{"id":"FG000","title":"12/24 Weeks Treatment","description":"Exenatide 2mg / 12/24 weeks treatment"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"110"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"101"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"9"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"6"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"104 were included in the safety set with 3 of inclusion/exclusion criteria deviations, 2 of treatment with prohibited concomitant medications, and 1 of enrolment before IRB approval excluded","groups":[{"id":"BG000","title":"12/24 Weeks Treatment","description":"Exenatide 2mg / 12/24 weeks treatment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"104"}]}],"measures":[{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<50 years","measurements":[{"groupId":"BG000","value":"44"}]},{"title":"Between 50 and 69 years","measurements":[{"groupId":"BG000","value":"58"}]},{"title":">=70 years","measurements":[{"groupId":"BG000","value":"2"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"62"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"42"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Adverse Events(AEs) and Serious Adverse Event(SAEs)","description":"was to estimate the incidence rates of adverse events (AEs) and serious adverse events (SAEs) in patients who are treated with 2 mg exenatide once weekly for type 2 diabetes mellitus in the normal clinical practice setting over a period of 12/24 weeks for long-term surveillance.","populationDescription":"Of 110 subjects, 104 were included in the safety set with 3 of inclusion/exclusion criteria deviations, 2 of treatment with prohibited concomitant medications, and 1 of enrolment before IRB approval excluded.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"baseline and 12/24 weeks","groups":[{"id":"OG000","title":"12/24 Weeks Treatment","description":"Exenatide 2mg / 12/24 weeks treatment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"}]}],"classes":[{"title":"rate of all AEs","categories":[{"measurements":[{"groupId":"OG000","value":"52.9","lowerLimit":"42.9","upperLimit":"62.6"}]}]},{"title":"rate of all SAEs","categories":[{"measurements":[{"groupId":"OG000","value":"3.8","lowerLimit":"1.04","upperLimit":"9.38"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c","description":"Change in HbA1c at 12 and 24 weeks from start of the treatment(24 weeks just for patients allocated in long-term treatment)","populationDescription":"Of 110 subjects, 104 were included in the safety set with 3 of inclusion/exclusion criteria deviations, 2 of treatment with prohibited concomitant medications, and 1 of enrolment before IRB approval excluded. Of 104 subjects, 1 subject who failed to receive the efficacy analysis was excluded, and 103 were included in the efficacy set.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage of Hba1c","timeFrame":"baseline and 12/24 weeks","groups":[{"id":"OG000","title":"12/24 Weeks Treatment","description":"Exenatide 2mg / 12/24 weeks treatment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.21","spread":"1.10"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Gloucose","description":"Change in Fasting plasma gloucose at 12 and 24 weeks from start of the treatment(24 weeks just for patients allocated in long-term treatment)","populationDescription":"Of 110 subjects, 104 were included in the safety set with 3 of inclusion/exclusion criteria deviations, 2 of treatment with prohibited concomitant medications, and 1 of enrolment before IRB approval excluded. Of 104 subjects, 1 subject who failed to receive the efficacy analysis was excluded, and 103 were included in the efficacy set.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mg/dL","timeFrame":"baseline and 12/24 weeks","groups":[{"id":"OG000","title":"12/24 Weeks Treatment","description":"Exenatide 2mg / 12/24 weeks treatment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.2","spread":"48.3"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight","description":"Change in body weight at 12 and 24 weeks from start of the treatment(24 weeks just for patients allocated in long-term treatment)","populationDescription":"Of 110 subjects, 104 were included in the safety set with 5 subjects of non-treatment with the study drug, 3 of inclusion/exclusion criteria deviations, 2 of treatment with prohibited concomitant medications, and 1 of enrolment before IRB approval excluded.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"kg","timeFrame":"baseline and 12/24 weeks","groups":[{"id":"OG000","title":"12/24 Weeks Treatment","description":"Exenatide 2mg / 12/24 weeks treatment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.95","spread":"2.86"}]}]}]},{"type":"SECONDARY","title":"Change in Vital Sign","description":"Change in vital sign at 12 and 24 weeks from start of the treatment(24 weeks just for patients allocated in long-term treatment)","populationDescription":"Of 110 subjects, 104 were included in the safety set with 5 subjects of non-treatment with the study drug, 3 of inclusion/exclusion criteria deviations, 2 of treatment with prohibited concomitant medications, and 1 of enrolment before IRB approval excluded.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmHg","timeFrame":"baseline and 12/24 weeks","groups":[{"id":"OG000","title":"12/24 Weeks Treatment","description":"Exenatide 2mg / 12/24 weeks treatment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"}]}],"classes":[{"title":"SBP","categories":[{"measurements":[{"groupId":"OG000","value":"-3.35","spread":"11.95"}]}]},{"title":"DBP","categories":[{"measurements":[{"groupId":"OG000","value":"-0.15","spread":"9.58"}]}]}]},{"type":"SECONDARY","title":"Evaluation of \"Subjective Improvement of Main Indication\"","description":"\"Subjective improvement of main indication\" will be assessed as \"improved,\" \"slightly improved,\" \"unchanged,\" \"aggravated,\" or \"unable to evaluate.\"","populationDescription":"Of 110 subjects, 104 were included in the safety set with 3 of inclusion/exclusion criteria deviations, 2 of treatment with prohibited concomitant medications, and 1 of enrolment before IRB approval excluded. Of 104 subjects, 1 subject who failed to receive the efficacy analysis was excluded, and 103 were included in the efficacy set.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"baseline and 12/24 weeks","groups":[{"id":"OG000","title":"12/24 Weeks Treatment","description":"Exenatide 2mg / 12/24 weeks treatment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"}]}],"classes":[{"title":"Improved","categories":[{"measurements":[{"groupId":"OG000","value":"84"}]}]},{"title":"Slightly improved","categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}]},{"title":"Unchanged","categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]},{"title":"Aggravated","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"unable to evaluate","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"12 weeks / 24 weeks","description":"Of 110 subjects, 104 were included in the safety set with 3 of inclusion/exclusion criteria deviations, 2 of treatment with prohibited concomitant medications, and 1 of enrolment before IRB approval excluded.","eventGroups":[{"id":"EG000","title":"12/24 Weeks Treatment","description":"Exenatide 2mg / 12/24 weeks treatment","seriousNumAffected":4,"seriousNumAtRisk":104,"otherNumAffected":55,"otherNumAtRisk":104}],"seriousEvents":[{"term":"Neuroendocrine tumor","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":104}]},{"term":"Acute gastroenteritis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":104}]},{"term":"Pelvic inflammatory disease","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":104}]},{"term":"Hyperglycemia including diarrhea","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":104}]}],"otherEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Of 110 subjects, 104 were included in the safety set with 3 of inclusion/exclusion criteria deviations, 2 of treatment with prohibited concomitant medications, and 1 of enrolment before IRB approval excluded.","stats":[{"groupId":"EG000","numEvents":16,"numAffected":15,"numAtRisk":104}]},{"term":"Injection site nodule","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Of 110 subjects, 104 were included in the safety set with 3 of inclusion/exclusion criteria deviations, 2 of treatment with prohibited concomitant medications, and 1 of enrolment before IRB approval excluded.","stats":[{"groupId":"EG000","numEvents":16,"numAffected":16,"numAtRisk":104}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Of 110 subjects, 104 were included in the safety set with 3 of inclusion/exclusion criteria deviations, 2 of treatment with prohibited concomitant medications, and 1 of enrolment before IRB approval excluded.","stats":[{"groupId":"EG000","numEvents":17,"numAffected":9,"numAtRisk":104}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Of 110 subjects, 104 were included in the safety set with 3 of inclusion/exclusion criteria deviations, 2 of treatment with prohibited concomitant medications, and 1 of enrolment before IRB approval excluded.","stats":[{"groupId":"EG000","numEvents":11,"numAffected":7,"numAtRisk":104}]},{"term":"injection site pruritus","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Of 110 subjects, 104 were included in the safety set with 3 of inclusion/exclusion criteria deviations, 2 of treatment with prohibited concomitant medications, and 1 of enrolment before IRB approval excluded.","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":104}]},{"term":"Dizziness","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Of 110 subjects, 104 were included in the safety set with 3 of inclusion/exclusion criteria deviations, 2 of treatment with prohibited concomitant medications, and 1 of enrolment before IRB approval excluded.","stats":[{"groupId":"EG000","numEvents":10,"numAffected":6,"numAtRisk":104}]},{"term":"Headache","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Of 110 subjects, 104 were included in the safety set with 3 of inclusion/exclusion criteria deviations, 2 of treatment with prohibited concomitant medications, and 1 of enrolment before IRB approval excluded.","stats":[{"groupId":"EG000","numEvents":10,"numAffected":6,"numAtRisk":104}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Of 110 subjects, 104 were included in the safety set with 3 of inclusion/exclusion criteria deviations, 2 of treatment with prohibited concomitant medications, and 1 of enrolment before IRB approval excluded.","stats":[{"groupId":"EG000","numEvents":10,"numAffected":7,"numAtRisk":104}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Of 110 subjects, 104 were included in the safety set with 3 of inclusion/exclusion criteria deviations, 2 of treatment with prohibited concomitant medications, and 1 of enrolment before IRB approval excluded.","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":104}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"* The Institution and PI shall provide the Company with copies of any materials relating to the Study that either intends to publish (or submit for publication) or make any presentations relating to, at least 30 days in advance of publication\n* At the request of the Company, the Institution and PI shall withhold publication for a period of 90 days from the date on which the Company receives the material."},"pointOfContact":{"title":"Hyun Jung Kang / Local Study Leader","organization":"Astrazeneca, Korea","email":"hyunjung.kang@astrazeneca.com","phone":"82 2 2188 0846","phoneExt":"0846"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D003924","term":"Diabetes Mellitus, Type 2"}],"ancestors":[{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077270","term":"Exenatide"}],"ancestors":[{"id":"D010455","term":"Peptides"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D014688","term":"Venoms"},{"id":"D045424","term":"Complex Mixtures"},{"id":"D014118","term":"Toxins, Biological"},{"id":"D001685","term":"Biological Factors"}]}},"hasResults":true}